Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by PD-1 and PD-L1 Inhibitors Revenue 1.4 Market Analysis by Type 1.4.1 Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 PD-1 Inhibitors 1.4.3 PD-L1 Inhibitors 1.5 Market by Application 1.5.1 Global PD-1 and PD-L1 Inhibitors Market Share by Application: 2020 VS 2026 1.5.2 Advanced Melanoma 1.5.3 Non-small Cell Lung Cancer (NSCLC) 1.5.4 Renal Cell Carcinoma 1.5.5 Bladder Cancer 1.5.6 Others 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 PD-1 and PD-L1 Inhibitors Market Perspective (2015-2026) 2.2 PD-1 and PD-L1 Inhibitors Growth Trends by Regions 2.2.1 PD-1 and PD-L1 Inhibitors Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 PD-1 and PD-L1 Inhibitors Historic Market Share by Regions (2015-2020) 2.2.3 PD-1 and PD-L1 Inhibitors Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 PD-1 and PD-L1 Inhibitors Market Growth Strategy 2.3.6 Primary Interviews with Key PD-1 and PD-L1 Inhibitors Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top PD-1 and PD-L1 Inhibitors Players by Market Size 3.1.1 Global Top PD-1 and PD-L1 Inhibitors Players by Revenue (2015-2020) 3.1.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Players (2015-2020) 3.1.3 Global PD-1 and PD-L1 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global PD-1 and PD-L1 Inhibitors Market Concentration Ratio 3.2.1 Global PD-1 and PD-L1 Inhibitors Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by PD-1 and PD-L1 Inhibitors Revenue in 2019 3.3 PD-1 and PD-L1 Inhibitors Key Players Head office and Area Served 3.4 Key Players PD-1 and PD-L1 Inhibitors Product Solution and Service 3.5 Date of Enter into PD-1 and PD-L1 Inhibitors Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global PD-1 and PD-L1 Inhibitors Historic Market Size by Type (2015-2020) 4.2 Global PD-1 and PD-L1 Inhibitors Forecasted Market Size by Type (2021-2026) 5 PD-1 and PD-L1 Inhibitors Breakdown Data by Application (2015-2026) 5.1 Global PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) 5.2 Global PD-1 and PD-L1 Inhibitors Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America PD-1 and PD-L1 Inhibitors Market Size (2015-2020) 6.2 PD-1 and PD-L1 Inhibitors Key Players in North America (2019-2020) 6.3 North America PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) 6.4 North America PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) 7 Europe 7.1 Europe PD-1 and PD-L1 Inhibitors Market Size (2015-2020) 7.2 PD-1 and PD-L1 Inhibitors Key Players in Europe (2019-2020) 7.3 Europe PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) 7.4 Europe PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) 8 China 8.1 China PD-1 and PD-L1 Inhibitors Market Size (2015-2020) 8.2 PD-1 and PD-L1 Inhibitors Key Players in China (2019-2020) 8.3 China PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) 8.4 China PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) 9 Japan 9.1 Japan PD-1 and PD-L1 Inhibitors Market Size (2015-2020) 9.2 PD-1 and PD-L1 Inhibitors Key Players in Japan (2019-2020) 9.3 Japan PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) 9.4 Japan PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia PD-1 and PD-L1 Inhibitors Market Size (2015-2020) 10.2 PD-1 and PD-L1 Inhibitors Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) 10.4 Southeast Asia PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) 11 India 11.1 India PD-1 and PD-L1 Inhibitors Market Size (2015-2020) 11.2 PD-1 and PD-L1 Inhibitors Key Players in India (2019-2020) 11.3 India PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) 11.4 India PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America PD-1 and PD-L1 Inhibitors Market Size (2015-2020) 12.2 PD-1 and PD-L1 Inhibitors Key Players in Central & South America (2019-2020) 12.3 Central & South America PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) 12.4 Central & South America PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) 13Key Players Profiles 13.1 Merck 13.1.1 Merck Company Details 13.1.2 Merck Business Overview and Its Total Revenue 13.1.3 Merck PD-1 and PD-L1 Inhibitors Introduction 13.1.4 Merck Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020)) 13.1.5 Merck Recent Development 13.2 Novartis 13.2.1 Novartis Company Details 13.2.2 Novartis Business Overview and Its Total Revenue 13.2.3 Novartis PD-1 and PD-L1 Inhibitors Introduction 13.2.4 Novartis Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) 13.2.5 Novartis Recent Development 13.3 Roche 13.3.1 Roche Company Details 13.3.2 Roche Business Overview and Its Total Revenue 13.3.3 Roche PD-1 and PD-L1 Inhibitors Introduction 13.3.4 Roche Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) 13.3.5 Roche Recent Development 13.4 AstraZeneca 13.4.1 AstraZeneca Company Details 13.4.2 AstraZeneca Business Overview and Its Total Revenue 13.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Introduction 13.4.4 AstraZeneca Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) 13.4.5 AstraZeneca Recent Development 13.5 Pfizer 13.5.1 Pfizer Company Details 13.5.2 Pfizer Business Overview and Its Total Revenue 13.5.3 Pfizer PD-1 and PD-L1 Inhibitors Introduction 13.5.4 Pfizer Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) 13.5.5 Pfizer Recent Development 13.6 GlaxoSmithKline Plc 13.6.1 GlaxoSmithKline Plc Company Details 13.6.2 GlaxoSmithKline Plc Business Overview and Its Total Revenue 13.6.3 GlaxoSmithKline Plc PD-1 and PD-L1 Inhibitors Introduction 13.6.4 GlaxoSmithKline Plc Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) 13.6.5 GlaxoSmithKline Plc Recent Development 13.7 Jiangsu HengRui Medicine Co.,Ltd 13.7.1 Jiangsu HengRui Medicine Co.,Ltd Company Details 13.7.2 Jiangsu HengRui Medicine Co.,Ltd Business Overview and Its Total Revenue 13.7.3 Jiangsu HengRui Medicine Co.,Ltd PD-1 and PD-L1 Inhibitors Introduction 13.7.4 Jiangsu HengRui Medicine Co.,Ltd Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) 13.7.5 Jiangsu HengRui Medicine Co.,Ltd Recent Development 13.8 Innovent + Eli Lilly 13.8.1 Innovent + Eli Lilly Company Details 13.8.2 Innovent + Eli Lilly Business Overview and Its Total Revenue 13.8.3 Innovent + Eli Lilly PD-1 and PD-L1 Inhibitors Introduction 13.8.4 Innovent + Eli Lilly Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) 13.8.5 Innovent + Eli Lilly Recent Development 13.9 Bristol Myers Squibb (BMS) 13.9.1 Bristol Myers Squibb (BMS) Company Details 13.9.2 Bristol Myers Squibb (BMS) Business Overview and Its Total Revenue 13.9.3 Bristol Myers Squibb (BMS) PD-1 and PD-L1 Inhibitors Introduction 13.9.4 Bristol Myers Squibb (BMS) Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) 13.9.5 Bristol Myers Squibb (BMS) Recent Development 14Analyst's Viewpoints/Conclusions 15Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

List of Tables Table 1. PD-1 and PD-L1 Inhibitors Key Market Segments Table 2. Key Players Covered: Ranking by PD-1 and PD-L1 Inhibitors Revenue Table 3. Ranking of Global Top PD-1 and PD-L1 Inhibitors Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of PD-1 Inhibitors Table 6. Key Players of PD-L1 Inhibitors Table 7. Global PD-1 and PD-L1 Inhibitors Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 8. Global PD-1 and PD-L1 Inhibitors Market Size by Regions (US$ Million): 2020 VS 2026 Table 9. Global PD-1 and PD-L1 Inhibitors Market Size by Regions (2015-2020) (US$ Million) Table 10. Global PD-1 and PD-L1 Inhibitors Market Share by Regions (2015-2020) Table 11. Global PD-1 and PD-L1 Inhibitors Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 12. Global PD-1 and PD-L1 Inhibitors Market Share by Regions (2021-2026) Table 13. Market Top Trends Table 14. Key Drivers: Impact Analysis Table 15. Key Challenges Table 16. PD-1 and PD-L1 Inhibitors Market Growth Strategy Table 17. Main Points Interviewed from Key PD-1 and PD-L1 Inhibitors Players Table 18. Global PD-1 and PD-L1 Inhibitors Revenue by Players (2015-2020) (Million US$) Table 19. Global PD-1 and PD-L1 Inhibitors Market Share by Players (2015-2020) Table 20. Global Top PD-1 and PD-L1 Inhibitors Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PD-1 and PD-L1 Inhibitors as of 2019) Table 21. Global PD-1 and PD-L1 Inhibitors by Players Market Concentration Ratio (CR5 and HHI) Table 22. Key Players Headquarters and Area Served Table 23. Key Players PD-1 and PD-L1 Inhibitors Product Solution and Service Table 24. Date of Enter into PD-1 and PD-L1 Inhibitors Market Table 25. Mergers & Acquisitions, Expansion Plans Table 26. Global PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) (Million US$) Table 27. Global PD-1 and PD-L1 Inhibitors Market Size Share by Type (2015-2020) Table 28. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2021-2026) Table 29. Global PD-1 and PD-L1 Inhibitors Market Size Share by Application (2015-2020) Table 30. Global PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) (Million US$) Table 31. Global PD-1 and PD-L1 Inhibitors Market Size Share by Application (2021-2026) Table 32. North America Key Players PD-1 and PD-L1 Inhibitors Revenue (2019-2020) (Million US$) Table 33. North America Key Players PD-1 and PD-L1 Inhibitors Market Share (2019-2020) Table 34. North America PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) (Million US$) Table 35. North America PD-1 and PD-L1 Inhibitors Market Share by Type (2015-2020) Table 36. North America PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) (Million US$) Table 37. North America PD-1 and PD-L1 Inhibitors Market Share by Application (2015-2020) Table 38. Europe Key Players PD-1 and PD-L1 Inhibitors Revenue (2019-2020) (Million US$) Table 39. Europe Key Players PD-1 and PD-L1 Inhibitors Market Share (2019-2020) Table 40. Europe PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) (Million US$) Table 41. Europe PD-1 and PD-L1 Inhibitors Market Share by Type (2015-2020) Table 42. Europe PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) (Million US$) Table 43. Europe PD-1 and PD-L1 Inhibitors Market Share by Application (2015-2020) Table 44. China Key Players PD-1 and PD-L1 Inhibitors Revenue (2019-2020) (Million US$) Table 45. China Key Players PD-1 and PD-L1 Inhibitors Market Share (2019-2020) Table 46. China PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) (Million US$) Table 47. China PD-1 and PD-L1 Inhibitors Market Share by Type (2015-2020) Table 48. China PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) (Million US$) Table 49. China PD-1 and PD-L1 Inhibitors Market Share by Application (2015-2020) Table 50. Japan Key Players PD-1 and PD-L1 Inhibitors Revenue (2019-2020) (Million US$) Table 51. Japan Key Players PD-1 and PD-L1 Inhibitors Market Share (2019-2020) Table 52. Japan PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) (Million US$) Table 53. Japan PD-1 and PD-L1 Inhibitors Market Share by Type (2015-2020) Table 54. Japan PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) (Million US$) Table 55. Japan PD-1 and PD-L1 Inhibitors Market Share by Application (2015-2020) Table 56. Southeast Asia Key Players PD-1 and PD-L1 Inhibitors Revenue (2019-2020) (Million US$) Table 57. Southeast Asia Key Players PD-1 and PD-L1 Inhibitors Market Share (2019-2020) Table 58. Southeast Asia PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) (Million US$) Table 59. Southeast Asia PD-1 and PD-L1 Inhibitors Market Share by Type (2015-2020) Table 60. Southeast Asia PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) (Million US$) Table 61. Southeast Asia PD-1 and PD-L1 Inhibitors Market Share by Application (2015-2020) Table 62. India Key Players PD-1 and PD-L1 Inhibitors Revenue (2019-2020) (Million US$) Table 63. India Key Players PD-1 and PD-L1 Inhibitors Market Share (2019-2020) Table 64. India PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) (Million US$) Table 65. India PD-1 and PD-L1 Inhibitors Market Share by Type (2015-2020) Table 66. India PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) (Million US$) Table 67. India PD-1 and PD-L1 Inhibitors Market Share by Application (2015-2020) Table 68. Central & South America Key Players PD-1 and PD-L1 Inhibitors Revenue (2019-2020) (Million US$) Table 69. Central & South America Key Players PD-1 and PD-L1 Inhibitors Market Share (2019-2020) Table 70. Central & South America PD-1 and PD-L1 Inhibitors Market Size by Type (2015-2020) (Million US$) Table 71. Central & South America PD-1 and PD-L1 Inhibitors Market Share by Type (2015-2020) Table 72. Central & South America PD-1 and PD-L1 Inhibitors Market Size by Application (2015-2020) (Million US$) Table 73. Central & South America PD-1 and PD-L1 Inhibitors Market Share by Application (2015-2020) Table 74. Merck Company Details Table 75. Merck Business Overview Table 76. Merck Product Table 77. Merck Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$) Table 78. Merck Recent Development Table 79. Novartis Company Details Table 80. Novartis Business Overview Table 81. Novartis Product Table 82. Novartis Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$) Table 83. Novartis Recent Development Table 84. Roche Company Details Table 85. Roche Business Overview Table 86. Roche Product Table 87. Roche Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$) Table 88. Roche Recent Development Table 89. AstraZeneca Company Details Table 90. AstraZeneca Business Overview Table 91. AstraZeneca Product Table 92. AstraZeneca Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$) Table 93. AstraZeneca Recent Development Table 94. Pfizer Company Details Table 95. Pfizer Business Overview Table 96. Pfizer Product Table 97. Pfizer Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$) Table 98. Pfizer Recent Development Table 99. GlaxoSmithKline Plc Company Details Table 100. GlaxoSmithKline Plc Business Overview Table 101. GlaxoSmithKline Plc Product Table 102. GlaxoSmithKline Plc Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$) Table 103. GlaxoSmithKline Plc Recent Development Table 104. Jiangsu HengRui Medicine Co.,Ltd Company Details Table 105. Jiangsu HengRui Medicine Co.,Ltd Business Overview Table 106. Jiangsu HengRui Medicine Co.,Ltd Product Table 107. Jiangsu HengRui Medicine Co.,Ltd Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$) Table 108. Jiangsu HengRui Medicine Co.,Ltd Recent Development Table 109. Innovent + Eli Lilly Business Overview Table 110. Innovent + Eli Lilly Product Table 111. Innovent + Eli Lilly Company Details Table 112. Innovent + Eli Lilly Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$) Table 113. Innovent + Eli Lilly Recent Development Table 114. Bristol Myers Squibb (BMS) Company Details Table 115. Bristol Myers Squibb (BMS) Business Overview Table 116. Bristol Myers Squibb (BMS) Product Table 117. Bristol Myers Squibb (BMS) Revenue in PD-1 and PD-L1 Inhibitors Business (2015-2020) (Million US$) Table 118. Bristol Myers Squibb (BMS) Recent Development Table 119. Research Programs/Design for This Report Table 120. Key Data Information from Secondary Sources Table 121. Key Data Information from Primary Sources List of Figures Figure 1. Global PD-1 and PD-L1 Inhibitors Market Share by Type: 2020 VS 2026 Figure 2. PD-1 Inhibitors Features Figure 3. PD-L1 Inhibitors Features Figure 4. Global PD-1 and PD-L1 Inhibitors Market Share by Application: 2020 VS 2026 Figure 5. Advanced Melanoma Case Studies Figure 6. Non-small Cell Lung Cancer (NSCLC) Case Studies Figure 7. Renal Cell Carcinoma Case Studies Figure 8. Bladder Cancer Case Studies Figure 9. Others Case Studies Figure 10. PD-1 and PD-L1 Inhibitors Report Years Considered Figure 11. Global PD-1 and PD-L1 Inhibitors Market Size YoY Growth 2015-2026 (US$ Million) Figure 12. Global PD-1 and PD-L1 Inhibitors Market Share by Regions: 2020 VS 2026 Figure 13. Global PD-1 and PD-L1 Inhibitors Market Share by Regions (2021-2026) Figure 14. Porter's Five Forces Analysis Figure 15. Global PD-1 and PD-L1 Inhibitors Market Share by Players in 2019 Figure 16. Global Top PD-1 and PD-L1 Inhibitors Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PD-1 and PD-L1 Inhibitors as of 2019 Figure 17. The Top 10 and 5 Players Market Share by PD-1 and PD-L1 Inhibitors Revenue in 2019 Figure 18. North America PD-1 and PD-L1 Inhibitors Market Size YoY Growth (2015-2020) (Million US$) Figure 19. Europe PD-1 and PD-L1 Inhibitors Market Size YoY Growth (2015-2020) (Million US$) Figure 20. China PD-1 and PD-L1 Inhibitors Market Size YoY Growth (2015-2020) (Million US$) Figure 21. Japan PD-1 and PD-L1 Inhibitors Market Size YoY Growth (2015-2020) (Million US$) Figure 22. Southeast Asia PD-1 and PD-L1 Inhibitors Market Size YoY Growth (2015-2020) (Million US$) Figure 23. India PD-1 and PD-L1 Inhibitors Market Size YoY Growth (2015-2020) (Million US$) Figure 24. Central & South America PD-1 and PD-L1 Inhibitors Market Size YoY Growth (2015-2020) (Million US$) Figure 25. Merck Total Revenue (US$ Million): 2019 Compared with 2018 Figure 26. Merck Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020) Figure 27. Novartis Total Revenue (US$ Million): 2019 Compared with 2018 Figure 28. Novartis Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020) Figure 29. Roche Total Revenue (US$ Million): 2019 Compared with 2018 Figure 30. Roche Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020) Figure 31. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018 Figure 32. AstraZeneca Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020) Figure 33. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 34. Pfizer Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020) Figure 35. GlaxoSmithKline Plc Total Revenue (US$ Million): 2019 Compared with 2018 Figure 36. GlaxoSmithKline Plc Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020) Figure 37. Jiangsu HengRui Medicine Co.,Ltd Total Revenue (US$ Million): 2019 Compared with 2018 Figure 38. Jiangsu HengRui Medicine Co.,Ltd Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020) Figure 39. Innovent + Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018 Figure 40. Innovent + Eli Lilly Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020) Figure 41. Bristol Myers Squibb (BMS) Total Revenue (US$ Million): 2019 Compared with 2018 Figure 42. Bristol Myers Squibb (BMS) Revenue Growth Rate in PD-1 and PD-L1 Inhibitors Business (2015-2020) Figure 43. Bottom-up and Top-down Approaches for This Report Figure 44. Data Triangulation Figure 45. Key Executives Interviewed

Merck Novartis Roche AstraZeneca Pfizer GlaxoSmithKline Plc Jiangsu HengRui Medicine Co.,Ltd Innovent + Eli Lilly Bristol Myers Squibb (BMS)